Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
advantage, amortization, chemotherapy, collaboration, compute, deducting, discrete, estimate, estimated, evolution, expected, half, highly, Identification, immaterial, inclusive, infrequently, injectable, institutional, judicial, marketplace, Molnupiravir, objective, occur, occurring, pathogenic, Paxlovid, permanent, presence, provision, rate, rebound, Remdesivir, roster, segment, segmentation, side, single, specialty, statutory, subgroup, supplier, tax, trial, unusual, voted
Removed:
amino, calcium, focusing, licensed, month, personnel, SRA, Vitamin
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view